Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2020	Dec. 31, 2019
Operating Loss Carryforwards [Line Items]
Income tax expense or benefit	$ 41,000	$ 0
Tax rate	21.00%	21.00%
Valuation allowance	$ 67,226,000	$ 63,411,000
Change in valuation allowance	3,800,000
Orphan Drug Credit	$ 8,988,000	$ 8,924,000
Operating loss carryforwards, Limitations on Use	The Company also had NOLs in Denmark of $198.3 million which have an indefinite life. Federal and state NOLs and R&D credit and ODC carryforwards are also subject to annual limitations in the event that cumulative changes in the ownership interests of significant stockholders exceed 50% over a three-year period, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986 (the “Code”).
Research and Development
Operating Loss Carryforwards [Line Items]
Tax allowance				101.50%
R&D Expenditure Credit
Operating Loss Carryforwards [Line Items]
Effective income tax rate reconciliation, tax credit payable	20.00%
Effective income tax rate reconciliation, net benefit of credit	15.00%
2020 through 2022 | Research and Development
Operating Loss Carryforwards [Line Items]
Tax allowance			130.00%
2023 through 2025 | Research and Development
Operating Loss Carryforwards [Line Items]
Tax allowance			108.00%
2026 | Research and Development
Operating Loss Carryforwards [Line Items]
Tax allowance			114.00%
Prior to April 2023 | R&D Expenditure Credit
Operating Loss Carryforwards [Line Items]
Effective income tax rate reconciliation, tax credit payable	13.00%
Effective income tax rate reconciliation, net benefit of credit	10.53%
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 43,600,000
Research and Development tax credits	1,200,000
Orphan Drug Credit	9,000,000
State
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	38,400,000
Denmark
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 198,300,000